Related Experiment Video
Updated: Sep 30, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.2K
Tofacitinib in paediatric dermatoses: a narrative review
Ishan Agarwal1, Maitreyee Panda1, Anupam Das2
1Department of Dermatology, Venereology, and Leprosy, IMS and SUM Hospital, Bhubaneshwar, Odisha, India.
Clinical and Experimental Dermatology
|March 13, 2022
Summary
Tofacitinib shows promise for pediatric skin conditions like alopecia areata and atopic dermatitis. Oral and topical formulations offer effective options, but careful risk-benefit assessment is crucial for young patients.
Area of Science:
- Dermatology
- Pharmacology
- Paediatric Medicine
Background:
- Tofacitinib has transformed adult dermatological treatments.
- Limited data exists on its use in children.
- Paediatric dermatoses require effective and safe therapeutic options.
Purpose of the Study:
- To review the evidence for tofacitinib's efficacy and safety in paediatric dermatological conditions.
- To summarize findings on both oral and topical tofacitinib use in children.
- To provide a basis for clinical decision-making regarding tofacitinib in paediatric patients.
Main Methods:
- A comprehensive literature search was conducted.
- Studies evaluating oral and topical tofacitinib in paediatric populations were analyzed.
- Evidence on effectiveness, safety, and tolerability was synthesized.
Main Results:
- Oral tofacitinib is effective for refractory juvenile dermatomyositis, severe alopecia areata, atopic dermatitis, and psoriasis.
- Topical tofacitinib demonstrates efficacy in treating vitiligo and halo naevus.
- The safety and tolerability profile in children requires careful consideration.
Conclusions:
- Tofacitinib (oral and topical) presents a viable treatment avenue for specific paediatric dermatoses.
- Individual risk-benefit assessment is essential before initiating tofacitinib therapy in children.
- Further research may clarify long-term outcomes and safety in this population.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
249
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
249
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
231
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
231
01:29Inflammatory Bowel Disease IV: Pharmacological Management
217
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
217
01:23Skin Diseases and Disorders
4.4K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
4.4K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
428
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
428